Intelligence Feed event · Macro · 2026-09-03

    Revolution Medicines Publishes Phase 1/2 Data for Daraxonrasib in NEJM with 42% ORR

    Question

    Revolution Medicines Publishes Phase 1/2 Data for Daraxonrasib in NEJM with 42% ORR

    Direct answer

    Revolution Medicines achieved clinical validation with the publication of Phase 1/2 data for RASONQUE (daraxonrasib) in the New England Journal of Medicine. The trial targeted previously treated patients with RAS-mutant metastatic non-small cell lung cancer. The drug demonstrated a 42% objective response rate and 16.0 months of median overall survival, supporting regulatory progression and clinical development momentum.

    Original publisher
    Market Ontology
    Evidence through
    2026-09-03
    Published
    2026-10-20
    Revision
    1 · 2026-10-20

    Cite as: Market Ontology, “Revolution Medicines Publishes Phase 1/2 Data for Daraxonrasib in NEJM with 42% ORR”, revision 1, evidence through 2026-09-03. https://marketontology.com/market-events/2026-09-03/revolution-medicines-publishes-phase-1-2-data-for-daraxonrasib-in-nejm-with-42-o-f74389

    MACRO
    Revolution Medicines Publishes Phase 1/2 Data for Daraxonrasib in NEJM with 42% ORR
    Revolution Medicines achieved clinical validation with the publication of Phase 1/2 data for RASONQUE (daraxonrasib) in the New England Journal of Medicine. The trial targeted previously treated patients with RAS-mutant metastatic non-small cell lung cancer. The drug demonstrated a 42% objective response rate and 16.0 months of median overall survival, supporting regulatory progression and clinical development momentum.
    RVMD
    Impact
    70
    SEP 3
    SIG
    92%
    RVMD
    Revolution Medicines Publishes Phase 1/2 Data for Daraxonrasib in NEJM with 42% ORR
    Revolution Medicines achieved clinical validation with the publication of Phase 1/2 data for RASONQUE (daraxonrasib) in the New England Journal of Medicine. The trial targeted previously treated patients with RAS-mutant metastatic non-small cell lung cancer. The drug demonstrated a 42% objective response rate and 16.0 months of median overall survival, supporting regulatory progression and clinical development momentum.
    → Positive Phase 1/2 oncology efficacy publication in NEJM derisks RVMD's lead clinical pipeline candidate, expanding the commercial NPV of its RAS portfolio.
    Impact
    Revolution Medicines achieved clinical validation with the publication of Phase 1/2 data for RASONQUE (daraxonrasib) in the New England Journal of Medicine. The trial targeted previously treated patients with RAS-mutant metastatic non-small cell lung cancer. The drug demonstrated a 42% objective response rate and 16.0 months of median overall survival, supporting regulatory progression and clinical development momentum.
    Affected
    RVMD
    Transmission
    Positive Phase 1/2 oncology efficacy publication in NEJM derisks RVMD's lead clinical pipeline candidate, expanding the commercial NPV of its RAS portfolio.

    How this development reaches the affected companies

    AssetExposure and channelDirectionEvidence
    RVMDpipeline clinical validation derisking regulatory approval pathwayUp1-5dNEJM publication showed 42% ORR and 16.0 months median overall survival in NSCLC.

    Does this development affect your holdings?

    Enter your holdings to check them against this and other recent developments, review the decision that matters most, then set a monitor.

    Check this development against my holdings

    Review your initial audit before choosing ongoing portfolio scanning at $79/month.

    What happened next

    Price follow-up pending — no stored daily closes for these assets yet.

    Closing prices from stored daily bars; returns measured from the last close on or before the event date. Not a recommendation.

    No verifiable public source recorded for this card.

    Related

    Check this development against my holdings

    See today's live cards

    Public pages are published 24 hours after the product shows them. Desk shows every catalyst, event and causal reading as it happens, mapped to your holdings.

    Open Desk — $399/month